Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of E/C/F/TAF versus E/C/F/TDF in treatment-naive adults with HIV-1
NL-OMON38426Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Virologic suppression at Week 48. Planned start Mar 2013; status: withdrawn.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON38426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38426.